GoKawiilGene therapy Otarmeni restores hearing in children with OTOF-linked deafness
In the CHORD clinical trial, 24 participants aged 10 months to 16 years with a rare genetic hearing loss (DFNB9, caused by OTOF gene mutations) received a single infusion of the gene therapy Otarmeni into one or both ears. About 80% of participants showed improved hearing within 24 weeks, and case reports describe children regaining the ability to respond to sound and music after treatment.
GoKawiil's interpretation of the reporting above, not reported fact.
The trial results suggest gene therapy could offer a durable fix for a specific genetic cause of deafness rather than relying solely on devices like cochlear implants, though long-term safety and durability data are still being gathered. Because OTOF mutations account for only a small share of congenital hearing loss, the approach may initially help a narrow patient population, and researchers may need similar targeted therapies for other genetic causes. The report also notes that not all Deaf people view such conditions as needing a cure, which could shape how widely the therapy is adopted.
- Otarmeni delivers a functional OTOF gene copy to inner-ear hair cells via a single surgical infusion.
- In the CHORD trial, about 80% of 24 young participants showed hearing improvement within 24 weeks.
- OTOF-related deafness affects only 1-8% of congenital hearing loss cases, limiting the therapy's direct applicability.
Source: nature.com — Udesky, 2026-09-30
Published there as: “Restoring hearing in people with a rare form of deafness”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.